Investigation of the effects of curcumin supplementation in patients with non-alcoholic fatty liver disease

Investigation of the effects of curcumin supplementation in patients with non-alcoholic fatty liver disease - Curcumin for fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033774

Enrollment

Registered

2018-11-22

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

Curcuminoinds placebo (lactose)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of non-alcoholic fatty liver disease according to liver sonography

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Hepatic Malignancy Hemochromatosis Alcohol or opium abuse

Design outcomes

Primary

Measure	Time frame
Effect of curcumin versus placebo on the severity of hepatic steatosis	—

Secondary

Measure	Time frame
Effect of curcumin versus placebo on liver enzymes, lipids and glucose	—

Countries

Asia(except Japan)

Contacts

Public ContactYunes Panahi

Baqiyatallah University of Medical Sciences, Tehran, Iran Pharmacotherapy Department

yunespanahi@yahoo.com+982182483393

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026